Updated on Jul 17, 2025 Share
Akadeum Life Sciences, a leader in buoyancy-based cell separation technology, announces the broad integration capability of its flagship product, microbubble-based cell separation.
Microbubble integration into existing platforms enables scaled-up centralized and decentralized cell therapies, reducing footprint and cost. By leveraging microbubble technology, users gain a reduced footprint for cell therapy manufacturing, seamless integration, and healthier cells.
Akadeum is unveiling this advancement and attending alongside partners at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting in New Orleans, May 13th-16th. Throughout the conference, multiple presentations demonstrate the ability of microbubbles to accelerate the next generation of cell therapies. The goal of Akadeum’s integration program has been to integrate microbubbles with practically any platform for any starting material and to support process development with a shelved GMP-grade product.
Akadeum’s ASGCT agenda includes:
To schedule a meeting at ASGCT, please visit https://www.akadeum.com/contact/
Akadeum Life Sciences is pioneering buoyancy-based separation technologies that enable more effective and scalable cell isolation. Our mission is to create separation technologies to advance human health. We envision a world where innovative separations empower researchers and clinicians to unlock breakthroughs in diagnostics, therapeutics, and basic research.
For more information, visit akadeum.com or follow our journey to improve cell therapy on LinkedIn.
Related News
Akadeum Life Sciences, the world leader in advanced cell separation technology, proudly announces a groundbreaking…
Akadeum Life Sciences, a pioneer in buoyancy-based cell separation technology, today announced the successful close…
Akadeum Life Sciences was honored with the Technology Disruptor of the Year Award at Advanced…
Contact Us
View Resources